Print PDF
CBI's Pharmaceutical Congress on Paragraph IV Disputes -- Chad Landmon Discusses Litigation Strategies, Generic Exclusivity Forfeiture and Recent Developments in Paragraph IV Disputes
October 23, 2008

During CBI's Pharmaceutical Congress on Paragraph IV Disputes in Philadelphia on October 15 and 16, 2008, Axinn partner Chad Landmon spoke extensively on numerous issues relating to Paragraph IV litigation.  Chad Landmon was a workshop leader during a pre-conference workshop focusing on the assessment of litigation strategies to proactively plan for Paragraph IV disputes.  Chad also moderated a panel discussing FDA's recent decisions relating to the forfeiture of the generic exclusivity period. 

 Please click here for the presentations that were used.  If you have any questions about the issues that were discussed, please contact Chad Landmon at (860) 275-8170.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.